iconstar paper   Hepatitis C Articles (HCV)  
Back grey arrow rt.gif
 
 
Abbvie 3D at ICAAC, Sovaldi/ledipasvir, Daclatasvir+SOF, Simeprevir+SOF, Merck's triple
 
 
  HCV Infection/Drug Use in Rural Appalachian/Kentucky: 54% HCV+, 31% were aware of status, 94% white, age 31, prescription opoids (OxyContin/illicit methadone or hydrocodone more common) - (09/16/14)
 
HCV Treatment Access Restrictions - HCV Can Be Eradicated ! - (09/16/14)
 
IDSA, HIVMA Call for State Medicaid Programs to Lift Hepatitis C Prescribing Restrictions from ID and HIV Doctors -IDSA/HIVMA - (09/16/14)
 
ICAAC: High SVR12 Rates in HCV Genotype 1b-Infected Patients Receiving Ombitasvir/ABT-450/r and Dasabuvir With or Without Ribavirin Regardless of Baseline Characteristics - (09/08/14)
 
ICAAC: TURQUOISE-I: SAFETY AND EFFICACY OF ABT-450/R/OMBITASVIR, DASABUVIR, AND RIBAVIRIN IN PATIENTS CO-INFECTED WITH HEPATITIS C AND HIV-1 - (09/08/14)
 
ICAAC: Drug-Drug Interactions of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir and Dasabuvir with HIV Protease Inhibitors - (09/08/14)
 
ICAAC: Drug-Drug Interactions with Direct Acting Antiviral Combination Therapy of ABT-450/r, Ombitasvir and Dasabuvir - (09/08/14)
 
ICAAC: Drug-Drug Interactions of the Direct Acting Antiviral Regimen of ABT-450/r, Ombitasvir and Dasabuvir with Emtricitabine + Tenofovir, Raltegravir, Rilpivirine and Efavirenz - (09/08/14)
 
ICAAC: Transient Indirect Bilirubin Elevations Associated With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin - (09/08/14)
 
ICAAC: Adverse Event Profile of the Interferon-free All-oral ABT-450/r/Ombitasvir, Dasabuvir, and Ribavirin Regimen in HCV Patients - (09/08/14)
 
ICAAC 2014 54th Interscience Conference on Antimicrobial Agents and Chemotherapy
September 5-9, 2014
Washington, DC
 
AASLD/EASL Special
Conference on Hepatitis C
New York City, New York
September 12 - 13
 
HCV at IAC/2014-Melbourne - (08/22/14)
 
IAC: Ledipasvir/Sofosbuvir is Safe and Effective as a Single-Tablet-Regimen for Treatment of Patients with Genotype 1 Chronic Hepatitis C Virus, Including those with Compensated Cirrhosis - (07/25/14)
 
IAC: SAPPHIRE-II Subgroup Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-experienced Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
 
IAC: SAPPHIRE-I Subpopulation Analysis: ABT-450/r/Ombitasvir (ABT-267), Dasabuvir (ABT-333), and Ribavirin Regimen Achieves High Sustained Virologic Response Rates 12 Weeks Post-treatment in Treatment-naïve Patients With Chronic HCV GT 1 Infection, Regardless of Baseline Characteristics - (07/25/14)
 
IAC: Abbvie 3D Regimen in HCV Genotype 1-Infected Patients on Methadone or Buprenorphine (07/21/14)
 
IAC: All-Oral Therapy with Sofosbuvir Plus Ribavirin for the Treatment of HCV Genotype 1, 2,3 and 4 Infection in Patients Coinfected with HIV (PHOTON-2) (07/21/14)
 
EASL/2012: Potent Viral Suppression With the All-Oral Combination of Daclatasvir (NS5A Inhibitor) and GS-7977 (Nucleotide NS5B Inhibitor), +/- Ribavirin, in Treatment-Naive Patients With Chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2) - (04/19/12)
 
EASL: Sustained Virologic Response With Daclatasvir Plus Sofosbuvir ± Ribavirin (RBV) in Chronic HCV Genotype (GT) 1-Infected Patients Who Previously Failed Telaprevir (TVR) or Boceprevir (BOC) - (04/27/13)
 
Daclatasvir+Sofosbuvir-new studies, VX135, Daclatasvir Phase 3 IFN-free, EMA Compassionate Use, Accelerated EMA Marketing Review Recommendation
 
EASL: Once-daily simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in HCV genotype-1 prior null responders with METAVIR F0-2: COSMOS study subgroup analysis - (04/14/14)
 
EASL: Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naïve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2) - (04/14/14)
 
Janssen Initiates Phase 3 OPTIMIST Trials of Once-Daily Simeprevir in Combination with Once-Daily Sofosbuvir for the Treatment of Genotype 1 Chronic Hepatitis C - (04/03/14)
 
Merck.....the acquisition by Merck of Idenix and its 2 nucleoside drug candidates has been completed http://www.natap.org/2014/HCV/060914_01.htm
 
Efficacy and safety of MK-5172 and MK-8742 ± RIBAVIRIN IN Hepatitis C Genotype 1 Infected Patients with cirrhosis or previous null response: the C-WORTHY Study - (04/11/14)
 
EASL: SAFETY AND EFFICACY OF THE ALL-ORAL REGIMEN OF MK-5172 / MK-8742 ± RIBAVIRIN IN TREATMENT-NAIVE, NONCIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION: THE C-WORTHy STUDY - (04/14/14)
 
EFFICACY AND SAFETY OF THE ALL-ORAL REGIMEN, MK-5172/MK-8742 +/- RBV FOR 12 WEEKS IN GT1 HCV/HIV CO-INFECTED PATIENTS: THE C-WORTHY STUDY - (04/11/14)
 
SVR AND SAFETY OF LOWER DOSES OF MK-5172 25 MG AND 50 MG DAILY FOR 12 WEEKS IN HCV GENOTYPE (G)1 TREATMENT-NAIVE NON-CIRRHOTIC PATIENTS - (04/11/14) 		 
 
 
 
  iconpaperstack View Older Articles   Back to Top   www.natap.org